SIM0501 + olaparib

SIM0501 + olaparib is a combination therapy consisting of SIM0501 (details on this agent are not available in the provided sources) and olaparib. Olaparib is a small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair. By inhibiting PARP, olaparib prevents cancer cells—especially those with BRCA mutations or homologous recombination deficiencies—from repairing their DNA, leading to cell death. Olaparib is approved for the treatment and maintenance of several cancers including ovarian, breast, pancreatic, prostate, fallopian tube, and peritoneal cancers[1][2][3][6][8]. The mechanism of action for SIM0501 cannot be determined from the available data.